- Home
- BIIB vs BBD Comparison
BIIB vs BBD Comparison
Compare BIIB & BBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- BBD
- Stock Information
- Founded
- BIIB 1978
- BBD 1943
- Country
- BIIB United States
- BBD Brazil
- Employees
- BIIB N/A
- BBD N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- BBD Major Banks
- Sector
- BIIB Health Care
- BBD Finance
- Exchange
- BIIB Nasdaq
- BBD Nasdaq
- Market Cap
- BIIB 19.9B
- BBD 23.4B
- IPO Year
- BIIB 1991
- BBD N/A
- Fundamental
- Price
- BIIB $124.40
- BBD $2.17
- Analyst Decision
- BIIB Buy
- BBD Strong Buy
- Analyst Count
- BIIB 27
- BBD 3
- Target Price
- BIIB $220.50
- BBD $2.55
- AVG Volume (30 Days)
- BIIB 1.8M
- BBD 39.1M
- Earning Date
- BIIB 04-23-2025
- BBD 05-08-2025
- Dividend Yield
- BIIB N/A
- BBD 3.14%
- EPS Growth
- BIIB 40.28
- BBD 21.38
- EPS
- BIIB 11.18
- BBD 0.26
- Revenue
- BIIB $9,675,900,000.00
- BBD $12,754,506,006.00
- Revenue This Year
- BIIB N/A
- BBD $68.29
- Revenue Next Year
- BIIB N/A
- BBD $9.98
- P/E Ratio
- BIIB $11.75
- BBD $7.89
- Revenue Growth
- BIIB N/A
- BBD 15.41
- 52 Week Low
- BIIB $128.51
- BBD $1.84
- 52 Week High
- BIIB $238.00
- BBD $2.98
- Technical
- Relative Strength Index (RSI)
- BIIB 32.01
- BBD 49.84
- Support Level
- BIIB $128.75
- BBD $2.19
- Resistance Level
- BIIB $144.07
- BBD $2.32
- Average True Range (ATR)
- BIIB 3.72
- BBD 0.05
- MACD
- BIIB -1.21
- BBD -0.01
- Stochastic Oscillator
- BIIB 11.38
- BBD 4.84
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About BBD Banco Bradesco Sa
Banco Bradesco is Brazil's second-largest private bank, with about 15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. Banking provides roughly 70% of profits, while the insurance segment contributes the remaining 30%. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.